Skip to content
Head to head

Krystal Biotech vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: KRYS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

KRYS +48.3%VRTX +18.7%
It’s close.
KRYSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price308.89515.02
Change today-2.19%-1.08%
1-year return+51.2%+22.0%
Market cap$9.15B$130.58B
52-week range212.02 – 382.54412.27 – 568.67
Valuation
P/E (TTM)41.9733.14
P/E percentile, own 5-yr range68th99th
P/B6.386.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)6.8415.32
Net profit (TTM)$202.69M$3.88B
Revenue (TTM)$470.03M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+30.2%+11.8%
Gross margin94.3%85.5%
Operating margin48.4%33.1%
Net margin47.9%30.7%
Free cash flow (TTM)$310.08M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership100.5%96.8%
Insider activity (12mo)19 buy / 25 sell28 buy / 22 sell
Short interest (% of float)10.3%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$393 (+27%)$624 (+21%)
StockVane view
StockVane Quant RatingD (88)C (68)
Company
Employees2956,400
Founded20161989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.